Ceptaris Therapeutics (Malvern, PA) a clinical-stage specialty pharmaceutical company focused on the treatment of mycosis fungoides, a type of cutaneous t-cell lymphoma, closed a $14.4M Series D financing. Participants include Vivo Ventures, Palo Alto Investors, Burrill & Co. and Aperture Venture Partners.

Thanx for your patience as we catch-up.